Evidence map›Paper›PMID 34535326›Full record

ReviewBlood reviews2022

Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues.

Robert J Kreitman, Evgeny Arons

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Blood reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Robert J KreitmanLaboratory of Molecular Biology, Clinical Center, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: kreitmar@mail.nih.gov.
Evgeny AronsLaboratory of Molecular Biology, Clinical Center, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
National Cancer Institute · USNational Institutes of Health · US

Funding

Development of Recombinant Toxins to Treat Hematologic MalignanciesZIABC010301 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KREITMAN, ROBERT · 2009 to 2025
$21.7M
Patterns of immune response in COVID-19 patientsZIABC011952 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KREITMAN, ROBERT · 2020 to 2025
$1.6M
6 · The paper itself

Abstract

Hairy cell leukemia (HCL) is an indolent B-cell malignancy, usually driven by the BRAF V600E mutation. For 30 years, untreated and relapsed HCL was successfully treated with purine analogs, but minimal residual disease (MRD) remained in most patients, eventually causing relapse. Repeated purine analogs achieve decreasing efficacy and increasing toxicity, particularly to normal T-cells. MRD-free complete remissions (CRs) are more common using rituximab with purine analogs in both 1

Indexed as

COVID-19PandemicsAntineoplastic AgentsHumansLeukemia, Hairy CellNeoplasm, ResidualProto-Oncogene Proteins B-rafPurinesRecurrenceRituximabAntineoplastic AgentsProto-Oncogene Proteins B-rafPurinesRituximabCladribineDabrafenibHairy cell leukemiaMinimal residual diseaseMoxetumomab pasudotoxRituximabTrametinibTreatmentVemurafenib

Identifiers

PMID34535326
PMCPMC8418384
OpenAlexW3196886681

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.